Buy Sutekast 12.5mg in UAE | Ernest Oncology – Oncology Meds Supplier

Sutekast 12.5mg Capsule: Advanced Multi-Kinase Inhibitor for Targeted Oncology Care

Are you searching for a reliable Sutekast 12.5 mg capsule exporter from India? Ernest Oncology, a premier division of Ernest Pharmaceutical Pvt. Ltd., is a leading international bulk supplier and distributor. We provide high-quality oncology solutions to the USA, UK (London), UAE (Abu Dhabi), Australia, and South Africa, ensuring streamlined logistics and professional B2B service.

Product Detail: What is Sutekast 12.5 mg?

Sutekast 12.5 mg contains Sunitinib Malate, a powerful multi-targeted receptor tyrosine kinase (RTK) inhibitor. The 12.5 mg strength is often used as a starting dose or for dose titration to manage aggressive tumor growth by disrupting the blood supply and cellular signaling of malignant cells. Manufactured under strict quality controls, Sutekast is a clinically equivalent alternative to global brands.

Therapeutic Indications:

Sutekast 12.5 mg is widely recognized for its efficacy in treating:

• Advanced Renal Cell Carcinoma (RCC): A primary treatment for advanced or metastatic kidney cancer.

• Gastrointestinal Stromal Tumor (GIST): Used when previous treatments like imatinib have failed or cannot be tolerated.

• Pancreatic Neuroendocrine Tumors (pNET): For progressive, well-differentiated tumors located in the pancreas.

• Adjuvant Treatment of RCC: For patients at high risk of recurrent kidney cancer following surgery.

Pharmacology and Mechanism of Action:

Sutekast works by blocking several enzymes called Tyrosine Kinases. These enzymes are found in receptors on the surface of both cancer cells and normal cells.

1. Anti-Angiogenesis: It blocks VEGFR (Vascular Endothelial Growth Factor Receptors), preventing the tumor from developing the new blood vessels it needs to "feed" and grow.

2. Anti-Proliferation: It targets PDGFR (Platelet-Derived Growth Factor Receptors) and KIT, which are vital for the survival and division of cancer cells.

By attacking the cancer from multiple angles, Sutekast 12.5 mg helps shrink tumors and delay disease progression.

Dosage and Administration Schedule:

• Cycle-Based Dosing: For RCC and GIST, the standard protocol often involves taking a total daily dose of 50 mg (four 12.5 mg capsules) for 4 weeks, followed by 2 weeks of rest.

• Continuous Dosing: For pNET, a lower daily dose (typically 37.5 mg) is often taken continuously.

• Administration: Capsules must be swallowed whole with water. They can be taken with or without food. Avoid grapefruit juice, as it may increase the concentration of the drug in the bloodstream to unsafe levels.

Important Safety Information:

Patients using Sutekast 12.5 mg should be monitored for:

• Hypertension: Blood pressure should be checked regularly.

• Hepatotoxicity: Liver function tests are required during treatment.

• Thyroid Dysfunction: Both hypothyroidism and hyperthyroidism can occur.

• Skin Reactions: "Hand-foot syndrome" (redness and peeling of skin on extremities) or skin/hair yellowing.

Why Partner with Ernest Oncology for Sutekast 12.5mg?

• Strategic Global Logistics: Direct shipping and rapid delivery to the USA, UK, UAE, Australia, and South Africa. 

• Authentic Indian Exports: We source from reputable, GMP-compliant manufacturers, ensuring product integrity.

• Competitive B2B Pricing: Specialized pricing models for oncology clinics, hospitals, and pharmacies.

• Expert Documentation: We handle all international pharmaceutical export regulations and customs paperwork.